Abstract:Introduction Previous studies suggested that estrogen receptor alpha (ERα) plays an important role in the chemoresistance of breast cancers. However, large random trials failed to demonstrate any benefit of the concurrent estrogen antagonist tamoxifen on the chemotherapy efficacy. Thus, in the present study, the importance of the role of ERα in the chemoresistance of breast cancer cells was investigated. Methods The ERα-transfected Bcap37 cells and natural ERα-positive T47D breast cancer cells were treated using chemotherapeutic agents with or without 17-beta estradiol (E2) pretreatment. Their viabilities were assessed using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assays. The dead cell rates were determined using propidium iodide dye exclusion tests, and the expression levels of Bcl-2 and Bax were detected through Western blot analysis. The effects of E2 on the growth of breast cancer cells were also determined via cell growth curve and cell cycle analysis. Results ERα activation by E2 increased the sensitivity of natural ERα-positive T47D breast cancer cells to chemotherapeutic agents. However, the increase in ERα expression in ERα-negative Bcap37 breast cancer cells also significantly increased their resistance. These phenomena cannot be explained by asserting that ERα mediated the chemoresistance of breast cancer cells by regulating the expression of Bcl-2 and Bax. Our findings show that ERα activation upregulated the expression of Bcl-2 in natural ERα-positive T47D breast cancer cells, whereas ERα activation by E2 downregulated and upregulated the Bcl-2 and Bax expression levels, respectively, in ERα-transfected Bcap37 cells. This phenomenon was due to the influence of ERα on the growth of breast cancer cells. Specifically, ERα activation enhanced the growth of natural ERα-positive breast cancer cells and thus increased their sensitivity to chemotherapeutic agents. However, ERα activation also inhibited the growth of ERα-transfected Bcap37 cells and increased the resistance of cancer cells to chemotherapeutic agents. Chemoresistance of ERα-transfected Bcap37 cells was only due to the specific growth inhibition by E2, which is not applicable to common ERα-positive breast cancer cells. Conclusions Although ERα was associated with chemoresistance of breast cancers, ERα itself did not mediate this resistance process.

Estrogen Stimulated Migration and Invasion of Estrogen Receptor-Negative Breast Cancer Cells Involves an Ezrin-Dependent Crosstalk Between G Protein-Coupled Receptor 30 and Estrogen Receptor Beta Signaling.

Ezrin T567 phosphorylation regulates migration and invasion of ectopic endometrial stromal cells by changing actin cytoskeleton

The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells

Overexpression of ERα Inhibits Proliferation and Invasion of MKN28 Gastric Cancer Cells by Suppressing Β-Catenin

Heregulin-β1-induced GPR30 upregulation promotes the migration and invasion potential of SkBr3 breast cancer cells via ErbB2/ErbB3-MAPK/ERK pathway.

Estradiol and tamoxifen induce cell migration through GPR30 and activation of focal adhesion kinase (FAK) in endometrial cancers with low or without nuclear estrogen receptor α (ERα)

Extra-Nuclear Signalling of Estrogen Receptor to Breast Cancer Cytoskeletal Remodelling, Migration and Invasion

Estrogen Related Receptor Alpha Triggers the Migration and Invasion of Endometrial Cancer Cells Via Up Regulation of TGFB1.

Estrogen-independent Effects of ER-α36 in ER-negative Breast Cancer

Nuclear Estrogen Receptor-Mediated Notch Signaling and GPR30-mediated PI3K/AKT Signaling in the Regulation of Endometrial Cancer Cell Proliferation.

Crosstalk Between Estrogen Receptor and Mitogen-Activated Protein Kinase Signaling in the Development and Progression of Endometrial Cancer

Estrogenic Transmembrane Receptor of GPR30 Mediates Invasion and Carcinogenesis by Endometrial Cancer Cell Line RL95-2

Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling.

Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway.

Estrogen Promotes the Metastasis of Non‑small Cell Lung Cancer Via Estrogen Receptor Β by Upregulation of Toll‑like Receptor 4 and Activation of the Myd88/nf‑κb/mmp2 Pathway.

CXCL1 Stimulates Migration and Invasion in ER‑negative Breast Cancer Cells Via Activation of the ERK/MMP2/9 Signaling Axis

Regulation of HRG-β1-induced Proliferation, Migration and Invasion of MCF-7 Cells by Upregulation of GPR30 Expression.

Low concentrations of 17β‐estradiol exacerbate tamoxifen resistance in breast cancer treatment through membrane estrogen receptor‐mediated signaling pathways

Posttranscriptional Control of PD-L1 Expression by 17Β-Estradiol Via PI3K/Akt Signaling Pathway in ERα-Positive Cancer Cell Lines.

17Β-Estradiol Activates PI3K/Akt Signaling Pathway by Estrogen Receptor (Er)-Dependent and ER-independent Mechanisms in Endometrial Cancer Cells

Tetrachlorobisphenol A and bisphenol AF induced cell migration by activating PI3K/Akt signaling pathway via G protein‐coupled estrogen receptor 1 in SK‐BR‐3 cells